Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
Kura Oncology, Inc.
Faron Pharmaceuticals Ltd
CellCentric Ltd.
Celgene
Treadwell Therapeutics, Inc
Pfizer
Prelude Therapeutics
Celgene
Celgene
S*BIO